Industrial Sonomechanics Publishes Groundbreaking Pharmacokinetic Study of Two Delta-8 THC Nanoemulsions
MIAMI, April 9, 2024 /PRNewswire/ -- Industrial Sonomechanics® (ISM) has recently completed a groundbreaking pre-clinical pharmacokinetic study, comparing two orally administered Delta-8 THC nanoemulsions (liquid and powdered) with a Delta-8 THC solution in MCT oil. The results demonstrate considerable advantages of nanoemulsions produced with ISM's ultrasonic equipment and NanoStabilizers®, and are detailed in a recent publication. This marks the industry's first pre-clinical study of Delta-8 THC nanoemulsions.
Study Aims and Design:
For years, ISM's ultrasonic equipment and NanoStabilizers® have enabled companies around the world to produce their own water-soluble liquid and powdered nano-formulations that are infused into beverages, edibles, and tablets, and significantly improve absorption profiles of the incorporated bioactive ingredients.
The main pharmacokinetic parameter of interest for most bioactives (cannabinoids, alkaloids, terpenes, etc.) is the rate of absorption into the bloodstream, characterized as the "onset time", "time to maximum bloodstream concentration", and/or "average bloodstream concentration over a time window of interest".
This study was aimed at evaluating the rate of oral absorption of Delta-8 THC formulated as two nanoemulsions: translucent liquid (made with NanoStabilizer®-LT) and powdered (made with NanoStabilizer®-LSO), and as an MCT oil solution. The study parameters were optimized for the rate of absorption evaluation, rather than other, less consequential parameters (absolute bioavailability, food effects, etc.).
Results: Nanoemulsions Very Significantly Outperform MCT Oil Solution
During the most important first hour after administration, NanoStabilizer®-LT and -LSO-based nanoemulsions provided 15.6x and 18.8x greater absorption of Delta-8 THC, respectively, than the MCT oil solution.
During the extended 4-hour period after administration, NanoStabilizer®-LT and -LSO-based nanoemulsions provided 4.1x and 3.4x greater absorption of Delta-8 THC, respectively, than the MCT oil solution.
Both nanoemulsions enabled a much more rapid onset time and a much shorter time to maximum bloodstreamconcentration (~5 min and <1 hour, respectively) than the MCT oil solution (~1 hour and 6 hours, respectively).
Translucent liquid and powderedDelta-8 THC nanoemulsions displayed similar pharmacokinetic profiles.
Conclusions:
Delta-8 THC nanoemulsions made with ISM's technology provide an almost immediate onset time and considerably greater absorption within time windows of interest.
ISM's nanoemulsions of bioactives (cannabinoids, alkaloids, terpenes, etc.) are potentially advantageous for creating fast-acting infused products, such as beverages, edibles, water-soluble powder mixes, tablets, and many others.
ISM is a U.S.-based R&D, equipment design & manufacturing, and process consulting firm specializing in high-intensity ultrasonic technology for the production of nano-formulations.
The Friends of the Uniformed Services University (Friends of USU) will host a lunch and panel discussion on Wednesday, May 22, 12:00-2:30 p.m. at the National Press Club in Washington, DC., to discuss the history, present state, and future of...
Between 13 May 2024 and 17 May 2024 EQT AB (LEI code 213800U7P9GOIRKCTB34) ("EQT") has repurchased in total 504,428 own ordinary shares (ISIN: SE0012853455).
The repurchases form part of the repurchase program of a maximum of 2,154,000 own ordinary...
Network Perception, innovators of operational technology (OT) solutions that visualize and secure the Connected Critical Infrastructure, is proud to announce that it has been recognized as a Global InfoSec Award winner, presented by Cyber Defense...
Advanced Prenatal Therapeutics, Inc. ("APT") is pleased to have received the California Investment Forum (CIF) 2024 Innovation Award for Breakthrough Medical Technology in Diagnosis and Treatment in recognition of APT's breakthrough technology, the...
LSU Health New Orleans announces the discovery and clinical advancement of a new non-opioid therapeutic candidate for treatment of acute, chronic, and neuropathic pain and migraine headaches which does not have the organ toxicity or addiction...
InfoVision, a leader in providing cutting-edge digital transformation solutions, is proud to announce its recognition as a ?Standout' in the ISG Case Study Research for 2023, within the Banking and Financial Services sector for North America.
This...